Point: Low-density lipoprotein cholesterol goals in patients with diabetes are not adequately based on evidence

被引：0
作者：
Gosmanov, Aidar R. [1 ]
机构：
[1] Emory Univ, Sch Med, Dept Med, Div Endocrinol Metab Lipids, Atlanta, GA 30303 USA
来源：
JOURNAL OF CLINICAL LIPIDOLOGY | 2010年 / 4卷 / 01期
关键词：
RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; ARM ASCOT-LLA; HYPERTENSIVE PATIENTS; ATORVASTATIN; PREVENTION; OUTCOMES; DISEASE; PRAVASTATIN; CORONARY;
D O I：
10.1016/j.jacl.2009.12.003
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：69 / 71
页数：3
相关论文
共 10 条
[1]  
[Anonymous], 2002, JAMA, V288, P2998
[2]  
[Anonymous], DIABETES CARE S1
[3]   Lipoprotein management in patients with cardiometabolic risk - Consensus conference report from the American diabetes association and the American college of cardiology foundation [J].
Brunzell, John D. ;
Davidson, Michael ;
Furberg, Curt D. ;
Goldberg, Ronald B. ;
Howard, Barbara V. ;
Stein, James H. ;
Witztum, Joseph L. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (15) :1512-1524
[4]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[5]  
Collins R, 2003, LANCET, V361, P2005
[6]   Efficacy and safe of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes - The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) [J].
Knopp, Robert H. ;
D'Emden, Michael ;
Smilde, Johan G. ;
Pocock, Stuart J. .
DIABETES CARE, 2006, 29 (07) :1478-1485
[7]   Current overview of statin-induced myopathy [J].
Rosenson, RS .
AMERICAN JOURNAL OF MEDICINE, 2004, 116 (06) :408-416
[8]   Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes:: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA) [J].
Sever, PS ;
Poulter, NR ;
Dahlöf, B ;
Wedel, H ;
Collins, R ;
Beevers, G ;
Caulfield, M ;
Kjeldsen, SE ;
Kristinsson, A ;
McInnes, GT ;
Mehlsen, J ;
Nieminen, M ;
O'Brien, E ;
Ostergren, J .
DIABETES CARE, 2005, 28 (05) :1151-1157
[9]   Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):: a multicentre randomised controlled trial [J].
Sever, PS ;
Dahlöf, B ;
Poulter, NR ;
Wedel, H ;
Beevers, G ;
Caulfield, M ;
Collins, R ;
Kjeldsen, SE ;
Kristinsson, A ;
McInnes, GT ;
Mehlsen, J ;
Nieminen, M ;
O'Brien, E ;
Östergren, J .
LANCET, 2003, 361 (9364) :1149-1158
[10]   Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial [J].
Shepherd, J ;
Blauw, GJ ;
Murphy, MB ;
Bollen, ELEM ;
Buckley, BM ;
Cobbe, SM ;
Ford, I ;
Gaw, A ;
Hyland, M ;
Jukema, JW ;
Kamper, AM ;
Macfarlane, PW ;
Meinders, AE ;
Norrie, J ;
Packard, CJ ;
Perry, IJ ;
Stott, DJ ;
Sweeney, BJ ;
Twomey, C ;
Westendorp, RGJ .
LANCET, 2002, 360 (9346) :1623-1630
1